Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Rhea-AI Summary

Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.

The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.

News Market Reaction – HROW

-1.33%

-1.33% Session close to close

In the Feb 18 session, HROW declined 1.33%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets clear expectations for Harrow’s Q4 and full-year 2025 earnings release on Mar...

Analysis

This announcement sets clear expectations for Harrow’s Q4 and full-year 2025 earnings release on March 2, 2026, followed by a conference call on March 3. In recent quarters, the company highlighted strong revenue growth, a swing to quarterly profitability, and expansion of its ophthalmic portfolio and guidance. Investors may focus on how upcoming results track against reaffirmed 2025 revenue guidance and prior operational milestones, as well as commentary on integration of acquired assets.

Key Figures

Earnings date: March 2, 2026 Conference call time: 8:00 a.m. Eastern Time Conference call date: March 3, 2026 +1 more

4 metrics

Earnings date March 2, 2026 Q4 and full-year 2025 results after market close

Conference call time 8:00 a.m. Eastern Time Results call on March 3, 2026

Conference call date March 3, 2026 Business update and Q4/FY 2025 discussion

Webcast replay duration 1 year Replay availability on company website

Historical Context

5 past events · Latest: Feb 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 03	Licensing update	Positive	+5.1%	Confirmed OSRX licensing and operations after a competitor exited California.
Feb 02	Guidance reaffirmed	Positive	+9.7%	Reaffirmed 2025 revenue guidance and detailed commercial expansion initiatives.
Nov 24	Investor conferences	Neutral	+0.2%	Announced participation in two December 2025 investor conferences.
Nov 18	Acquisition close	Positive	-1.4%	Closed acquisition of Melt Pharmaceuticals, adding MELT pipeline assets.
Nov 10	Earnings release	Positive	+0.6%	Reported strong Q3 2025 revenue growth and positive adjusted EBITDA.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive updates (guidance reaffirmation, licensing strength, earnings) often coincided with positive price reactions, while the Melt acquisition saw a modest negative divergence.

Recent Company History

Over the last few months, Harrow reported strong fundamentals and strategic expansion. On Nov 10, 2025, Q3 2025 results showed revenue of $71.6 million and a swing to quarterly profitability, with a mild positive share reaction. The Nov 18, 2025 Melt Pharmaceuticals acquisition added late-stage assets but saw a small price decline. In early Feb 2026, reaffirmed $270–$280 million 2025 revenue guidance and operational expansion drove a 9.67% move, and confirmation of OSRX licensing strength followed with another gain. Today’s earnings-date notice fits into this cadence of frequent investor communications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update.

Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.

About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
VP of Investor Relations & Communications
mbiega@harrowinc.com
617-913-8890

FAQ

When will Harrow (HROW) release its Q4 and year-end 2025 results?

Harrow will release fourth quarter and year-end 2025 results after market close on March 2, 2026. According to the company, the Q4 Letter to Stockholders will be posted on its Investors webpage alongside the release.

What time is Harrow's (HROW) conference call and webcast for the March 2026 results?

The conference call and live webcast are scheduled for 8:00 a.m. Eastern Time on March 3, 2026. According to the company, the event will discuss results and provide a business update for investors.

How can investors access Harrow's (HROW) live webcast for the March 3, 2026 call?

Investors can access the live webcast via Harrow's Investors page on its website. According to the company, a replay will be available on the website for one year after the event.

Will Harrow (HROW) provide a replay of the March 3, 2026 earnings webcast?

Yes, Harrow will make a replay available on its website for one year. According to the company, the replay will be posted on the Investors page following the live webcast.

How do I join Harrow's (HROW) March 3, 2026 conference call by phone?

Telephone participants must register in advance to receive dial-in details and a PIN. According to the company, registrants will get a confirmation email with a unique dial-in number and PIN.

Where will Harrow (HROW) post its Q4 2025 Letter to Stockholders and related materials?

Harrow will post the Q4 2025 Letter to Stockholders on the Investors section of its corporate website. According to the company, materials related to the release and webcast will be accessible there.